Author:
Elleder Daniel,Baiga Thomas J,Russell Rebecca L,Naughton John A,Hughes Stephen H,Noel Joseph P,Young John AT
Abstract
Abstract
Background
Despite the effectiveness of highly active antiretroviral therapy (HAART), there remains an urgent need to develop new human immunodeficiency virus type 1 (HIV-1) inhibitors with better pharmacokinetic properties that are well tolerated, and that block common drug resistant virus strains.
Methods
Here we screened an in-house small molecule library for novel inhibitors of HIV-1 replication.
Results
An active compound containing a 3-aminoimidazo[1,2-a]pyridine scaffold was identified and quantitatively characterized as a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Conclusions
The potency of this compound coupled with its inexpensive chemical synthesis and tractability for downstream SAR analysis make this inhibitor a suitable lead candidate for further development as an antiviral drug.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference19 articles.
1. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X: HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2011. Epub 2011/04/28 10.1002/med.20241
2. Schreiber SL: Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287: 1964-1969. 10.1126/science.287.5460.1964
3. Domling A, Ugi II: Multicomponent reactions with isocyanides. Angew Chem Int Ed Engl 2000, 39: 3168-3210. 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U
4. Dolle RE: Comprehensive survey of combinatorial library synthesis: 2004. J Comb Chem 2005, 7: 739-798. 10.1021/cc050082t
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46: 3-26. 10.1016/S0169-409X(00)00129-0
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献